NO20072974L - Fenylpiperazinderivater med en kombinasjon av partiell dopamin-D2-receptoragonisme og serotoningjenopptaksinhibering - Google Patents

Fenylpiperazinderivater med en kombinasjon av partiell dopamin-D2-receptoragonisme og serotoningjenopptaksinhibering

Info

Publication number
NO20072974L
NO20072974L NO20072974A NO20072974A NO20072974L NO 20072974 L NO20072974 L NO 20072974L NO 20072974 A NO20072974 A NO 20072974A NO 20072974 A NO20072974 A NO 20072974A NO 20072974 L NO20072974 L NO 20072974L
Authority
NO
Norway
Prior art keywords
serotonin reuptake
combination
reuptake inhibition
phenylpiperazine derivatives
receptor agonism
Prior art date
Application number
NO20072974A
Other languages
English (en)
Norwegian (no)
Inventor
Gustaaf J M Van Scharrenburg
Roelof W Feenstra
Andrew C Mccreary
Maria L Pras-Raves
Mayke B Hesselink
Jan-Willem Terpstra
Axel Stoit
Bernard J Van Vliet
Cornelis G Kruse
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of NO20072974L publication Critical patent/NO20072974L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Fats And Perfumes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20072974A 2004-12-08 2007-06-11 Fenylpiperazinderivater med en kombinasjon av partiell dopamin-D2-receptoragonisme og serotoningjenopptaksinhibering NO20072974L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63407404P 2004-12-08 2004-12-08
EP04106394 2004-12-08
PCT/EP2005/056508 WO2006061379A1 (fr) 2004-12-08 2005-12-06 Derives de phenylpiperazine presentant un agonisme partiel des recepteurs d2 de la dopamine combine a une inhibition du recaptage de la serotonine

Publications (1)

Publication Number Publication Date
NO20072974L true NO20072974L (no) 2007-08-23

Family

ID=35744728

Family Applications (4)

Application Number Title Priority Date Filing Date
NO20072974A NO20072974L (no) 2004-12-08 2007-06-11 Fenylpiperazinderivater med en kombinasjon av partiell dopamin-D2-receptoragonisme og serotoningjenopptaksinhibering
NO20072977A NO20072977L (no) 2004-12-08 2007-06-11 Aryloksyetylaminderivater med en kombinasjon av partiell dopamin-D2-receptoragonisme og serotoningjenopptaksinhibering
NO20072981A NO20072981L (no) 2004-12-08 2007-06-11 Fenylpiperazinderivater med en kombinasjon av partiell dopamin-D2-receptoragonisme og serotoningjenopptaksinhibering
NO20072969A NO20072969L (no) 2004-12-08 2007-06-11 Fenylpiperazinderivater med en kombinasjon av partiell dopamin-D2-receptoragonisme og serotoningjenopptaksinhibering

Family Applications After (3)

Application Number Title Priority Date Filing Date
NO20072977A NO20072977L (no) 2004-12-08 2007-06-11 Aryloksyetylaminderivater med en kombinasjon av partiell dopamin-D2-receptoragonisme og serotoningjenopptaksinhibering
NO20072981A NO20072981L (no) 2004-12-08 2007-06-11 Fenylpiperazinderivater med en kombinasjon av partiell dopamin-D2-receptoragonisme og serotoningjenopptaksinhibering
NO20072969A NO20072969L (no) 2004-12-08 2007-06-11 Fenylpiperazinderivater med en kombinasjon av partiell dopamin-D2-receptoragonisme og serotoningjenopptaksinhibering

Country Status (18)

Country Link
EP (4) EP1824480A1 (fr)
JP (4) JP2008523029A (fr)
KR (4) KR20070085988A (fr)
AT (2) ATE401883T1 (fr)
AU (4) AU2005313312A1 (fr)
BR (1) BRPI0518613A2 (fr)
CA (4) CA2587357A1 (fr)
DE (2) DE602005008471D1 (fr)
DK (2) DK1827427T3 (fr)
ES (2) ES2311245T3 (fr)
HR (2) HRP20080538T3 (fr)
IL (4) IL183062A0 (fr)
NO (4) NO20072974L (fr)
PL (2) PL1827427T3 (fr)
PT (2) PT1827427E (fr)
RU (4) RU2007125658A (fr)
SI (2) SI1827427T1 (fr)
WO (4) WO2006061378A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2641120A1 (fr) * 2006-01-30 2007-08-02 Speedel Experimenta Ag Procede de preparation de composes organiques
US8063062B2 (en) 2006-12-20 2011-11-22 Solvay Pharmaceuticals B.V. Compounds with a combination of cannabinoid-CB1 antagonism and acetylcholinesterase inhibition
WO2008084057A1 (fr) * 2007-01-10 2008-07-17 Solvay Pharmaceuticals B.V. Composés antagonistes des cannabinoïdes cb1 et inhibiteurs de la réabsorption de la sérotonine
US8138174B2 (en) 2007-01-10 2012-03-20 Solvay Pharmaceuticals B.V. Compounds with a combination of cannabinoid CB1 antagonism and serotonin reuptake inhibition
JP5431305B2 (ja) * 2007-04-23 2014-03-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 高速解離性ドパミン２受容体アンタゴニストとしての４−アルコキシピリダジン誘導体
RU2489431C2 (ru) * 2007-04-23 2013-08-10 Янссен Фармацевтика Н.В. Тиа(диа)золы как быстро диссоциирующие антагонисты рецептора допамина 2
AU2008240727C1 (en) * 2007-04-23 2013-10-03 Janssen Pharmaceutica N.V. Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists
CN103360342B (zh) * 2012-04-09 2015-12-16 江苏恩华药业股份有限公司 3-氰基苯胺烷基芳基哌嗪衍生物及在制备药物中的应用
CN103570698B (zh) * 2012-08-01 2016-08-03 江苏恩华药业股份有限公司 用于制备维拉佐酮的化合物及其中间体和应用
ITMI20130392A1 (it) * 2013-03-15 2014-09-16 Dipharma Francis Srl Sintesi di un inibitore della ricaptazione della serotonina
US9725463B2 (en) 2013-06-21 2017-08-08 Lupin Limited Substituted heterocyclic compounds as CRAC modulators
EP3013810A1 (fr) 2013-06-24 2016-05-04 Lupin Limited Dérivés de chromane et de chromène et leur utilisation en tant que modulateurs de crac
WO2015014256A1 (fr) 2013-07-29 2015-02-05 Sunshine Lake Pharma Co., Ltd. Composés hétéroaryle substitués et procédés d'utilisation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692264B1 (fr) * 1992-06-12 1994-08-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
EP0900792B1 (fr) * 1997-09-02 2003-10-29 Duphar International Research B.V Dérivés de pipéridine et de pipérazine comme agonistes du récepteur 5-HT1
EP1070050A1 (fr) * 1998-04-08 2001-01-24 American Home Products Corporation N-aryloxyethyl-indoly-alkylamines utilisees pour le traitement de la depression (principes actifs de recepteurs du type 5-ht1a)
JP2003521443A (ja) * 1998-06-19 2003-07-15 ハー・ルンドベック・アクチエゼルスカベット ４，５，６及び７−インドール及びインドリン誘導体、その製造方法及びその使用方法
AR022303A1 (es) * 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
NZ517900A (en) * 1999-08-23 2003-08-29 Solvay Pharm Bv Phenylpiperazines useful as serotonin reuptake inhibitors
US7482465B2 (en) * 2002-12-10 2009-01-27 Merck Patent Gmbh Indol derivatives and their use as 5-HT ligands

Also Published As

Publication number Publication date
DK1827427T3 (da) 2008-11-24
CA2587202A1 (fr) 2006-06-15
PT1824479E (pt) 2009-01-30
DK1824479T3 (da) 2009-03-09
PT1827427E (pt) 2008-11-03
PL1824479T3 (pl) 2009-04-30
JP2008523030A (ja) 2008-07-03
ES2311245T3 (es) 2009-02-01
AU2005313311A1 (en) 2006-06-15
WO2006061378A1 (fr) 2006-06-15
EP1827427A1 (fr) 2007-09-05
KR20070085988A (ko) 2007-08-27
AU2005313391A1 (en) 2006-06-15
KR20070085975A (ko) 2007-08-27
CA2587559A1 (fr) 2006-06-15
JP2008537725A (ja) 2008-09-25
SI1827427T1 (sl) 2008-12-31
BRPI0518613A2 (pt) 2008-11-25
ES2317335T3 (es) 2009-04-16
KR20070085916A (ko) 2007-08-27
EP1824479A1 (fr) 2007-08-29
NO20072981L (no) 2007-09-05
CA2587357A1 (fr) 2006-06-15
JP2008523031A (ja) 2008-07-03
DE602005008471D1 (de) 2008-09-04
IL183063A0 (en) 2007-09-20
IL183061A0 (en) 2007-09-20
DE602005010902D1 (de) 2008-12-18
NO20072977L (no) 2007-09-05
RU2007125658A (ru) 2009-01-20
KR20070085959A (ko) 2007-08-27
EP1827427B1 (fr) 2008-07-23
AU2005313390A1 (en) 2006-06-15
WO2006061376A1 (fr) 2006-06-15
IL183062A0 (en) 2007-09-20
WO2006061379A1 (fr) 2006-06-15
HRP20090015T3 (en) 2009-02-28
AU2005313312A1 (en) 2006-06-15
NO20072969L (no) 2007-08-31
ATE413173T1 (de) 2008-11-15
ATE401883T1 (de) 2008-08-15
SI1824479T1 (sl) 2009-04-30
WO2006061377A1 (fr) 2006-06-15
RU2007125659A (ru) 2009-01-20
HRP20080538T3 (en) 2008-12-31
EP1824480A1 (fr) 2007-08-29
IL183064A0 (en) 2007-09-20
EP1824479B1 (fr) 2008-11-05
RU2007125661A (ru) 2009-01-20
RU2007125660A (ru) 2009-01-20
PL1827427T3 (pl) 2009-01-30
JP2008523029A (ja) 2008-07-03
EP1827426A1 (fr) 2007-09-05
CA2587381A1 (fr) 2006-06-15

Similar Documents

Publication Publication Date Title
NO20072969L (no) Fenylpiperazinderivater med en kombinasjon av partiell dopamin-D2-receptoragonisme og serotoningjenopptaksinhibering
SG151254A1 (en) Substituted morpholine and thiomorpholine derivatives
HRP20090235A2 (en) Carbonylated (aza) cyclohexanes as dopamine d3 receptor ligands
CY1108230T1 (el) Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
MX2009004900A (es) Arilamidas sustituidas por tiazol u oxazol.
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
MXPA05010000A (es) Derivados de p-diaminobenceno substituidos.
MX2009003713A (es) Inhibidor de progresion de enfermedad de alzheimer que contiene un compuesto heterociclico con estructura especifica.
TW200718692A (en) Dihydrobenzofuran derivatives and uses thereof
NO20073941L (no) Dihydroimidazotiazolderivater
UA94603C2 (ru) Производные тетрагидронафталина, способ их получения и их применения в качестве ингибиторов воспаления
MXPA05009282A (es) Derivados de anilina sustituidos.
TW200631952A (en) Benzdioxan piperazine derivatives with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
TW200634009A (en) Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition
TW200633987A (en) Phenylpiperazines with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
SG171472A1 (en) Substituted aniline derivatives
TW200716555A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
WO2007004041A3 (fr) Nouveaux composes ainsi qu'utilisation pharmaceutique de ceux-ci
NO20073390L (no) Fenylpiperaziner med en kombinasjon av affinitet for dopamin-D2-reseptorer og serotoningjenopptaksseter

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application